Surveillance Guidelines for Hereditary Colorectal Cancer Syndromes

  • Neda Stjepanovic
  • Leticia Moreira
  • Judith Balmaña
  • Joan Brunet


The identification of hereditary colorectal cancer syndromes allows the prevention of colorectal and related extracolonic cancers and the possibility of genetic counseling to family members. The management of these syndromes requires a multidisciplinary approach, including counseling and genetic testing, screening recommendations, prevention options, and treatment strategies. Gene-specific risk estimations are leading to adapt surveillance recommendations for some Lynch and polyposis patients. New techniques such as chromoendoscopy are being incorporated to screening procedures in order to increase adenoma detection. This chapter reviews the surveillance guidelines of the most common hereditary colorectal syndromes, the types of recommendation, and the quality of evidence for each one.


Surveillance Prevention Screening Guidelines 

R eferences

  1. 1.
    Moller P, Seppala T, Bernstein I, et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut. 2017;66:464–72.CrossRefGoogle Scholar
  2. 2.
    Jarvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118:829–34.CrossRefGoogle Scholar
  3. 3.
    Jarvinen HJ, Mecklin JP, Sistonen P. Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 1995;108:1405–11.CrossRefGoogle Scholar
  4. 4.
    Jarvinen HJ, Renkonen-Sinisalo L, Aktan-Collan K, et al. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol. 2009;27:4793–7.CrossRefGoogle Scholar
  5. 5.
    de Vos tot Nederveen Cappel WH, Nagengast FM, Griffioen G, et al. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis Colon Rectum. 2002;45:1588–94.CrossRefGoogle Scholar
  6. 6.
    Engel C, Rahner N, Schulmann K, et al. Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. Clin Gastroenterol Hepatol. 2010;8:174–82.CrossRefGoogle Scholar
  7. 7.
    Stuckless S, Green JS, Morgenstern M, et al. Impact of colonoscopic screening in male and female Lynch syndrome carriers with an MSH2 mutation. Clin Genet. 2012;82:439–45.CrossRefGoogle Scholar
  8. 8.
    Vasen HF, Abdirahman M, Brohet R, et al. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. Gastroenterology. 2010;138:2300–6.CrossRefGoogle Scholar
  9. 9.
    Dove-Edwin I, Sasieni P, Adams J, et al. Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. BMJ. 2005;331:1047.CrossRefGoogle Scholar
  10. 10.
    Edelstein DL, Axilbund J, Baxter M, et al. Rapid development of colorectal neoplasia in patients with Lynch syndrome. Clin Gastroenterol Hepatol. 2011;9:340–3.CrossRefGoogle Scholar
  11. 11.
    De Jong AE, Morreau H, Van Puijenbroek M, et al. The role of mismatch repair gene defects in the development of adenomas in patients with HNPCC. Gastroenterology. 2004;126:42–8.CrossRefGoogle Scholar
  12. 12.
    Vasen HF, Taal BG, Nagengast FM, et al. Hereditary nonpolyposis colorectal cancer: results of long-term surveillance in 50 families. Eur J Cancer. 1995;31A:1145–8.CrossRefGoogle Scholar
  13. 13.
    Renkonen-Sinisalo L, Aarnio M, Mecklin JP, et al. Surveillance improves survival of colorectal cancer in patients with hereditary nonpolyposis colorectal cancer. Cancer Detect Prev. 2000;24:137–42.PubMedGoogle Scholar
  14. 14.
    Lindberg LJ, Ladelund S, Frederiksen BL, et al. Outcome of 24 years national surveillance in different hereditary colorectal cancer subgroups leading to more individualised surveillance. J Med Genet. 2016.Google Scholar
  15. 15.
    Bonadona V, Bonaiti B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011;305:2304–10.CrossRefGoogle Scholar
  16. 16.
    Jenkins MA, Dowty JG, Ait Ouakrim D, et al. Short-term risk of colorectal cancer in individuals with lynch syndrome: a meta-analysis. J Clin Oncol. 2015;33:326–31.CrossRefGoogle Scholar
  17. 17.
    Senter L, Clendenning M, Sotamaa K, et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology. 2008;135:419–28.CrossRefGoogle Scholar
  18. 18.
    Baglietto L, Lindor NM, Dowty JG, et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst. 2010;102:193–201.CrossRefGoogle Scholar
  19. 19.
    Hurlstone DP, Karajeh M, Cross SS, et al. The role of high-magnification-chromoscopic colonoscopy in hereditary nonpolyposis colorectal cancer screening: a prospective “back-to-back” endoscopic study. Am J Gastroenterol. 2005;100:2167–73.CrossRefGoogle Scholar
  20. 20.
    Rahmi G, Lecomte T, Malka D, et al. Impact of chromoscopy on adenoma detection in patients with Lynch syndrome: a prospective, multicenter, blinded, tandem colonoscopy study. Am J Gastroenterol. 2015;110:288–98.CrossRefGoogle Scholar
  21. 21.
    Capelle LG, Van Grieken NC, Lingsma HF, et al. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology. 2010;138:487–92.CrossRefGoogle Scholar
  22. 22.
    Win AK, Lindor NM, Young JP, et al. Risks of primary extracolonic cancers following colorectal cancer in Lynch syndrome. J Natl Cancer Inst. 2012;104:1363–72.CrossRefGoogle Scholar
  23. 23.
    Park YJ, Shin KH, Park JG. Risk of gastric cancer in hereditary nonpolyposis colorectal cancer in Korea. Clin Cancer Res. 2000;6:2994–8.PubMedGoogle Scholar
  24. 24.
    Renkonen-Sinisalo L, Sipponen P, Aarnio M, et al. No support for endoscopic surveillance for gastric cancer in hereditary non-polyposis colorectal cancer. Scand J Gastroenterol. 2002;37:574–7.CrossRefGoogle Scholar
  25. 25.
    Vasen HF, Blanco I, Aktan-Collan K, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut. 2013;62:812–23.CrossRefGoogle Scholar
  26. 26.
    Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110:223–62; quiz 263CrossRefGoogle Scholar
  27. 27.
    Koornstra JJ. Small bowel endoscopy in familial adenomatous polyposis and Lynch syndrome. Best Pract Res Clin Gastroenterol. 2012;26:359–68.CrossRefGoogle Scholar
  28. 28.
    Schulmann K, Brasch FE, Kunstmann E, et al. HNPCC-associated small bowel cancer: clinical and molecular characteristics. Gastroenterology. 2005;128:590–9.CrossRefGoogle Scholar
  29. 29.
    ten Kate GL, Kleibeuker JH, Nagengast FM, et al. Is surveillance of the small bowel indicated for Lynch syndrome families? Gut. 2007;56:1198–201.CrossRefGoogle Scholar
  30. 30.
    Saurin JC, Pilleul F, Soussan EB, et al. Small-bowel capsule endoscopy diagnoses early and advanced neoplasms in asymptomatic patients with Lynch syndrome. Endoscopy. 2010;42:1057–62.CrossRefGoogle Scholar
  31. 31.
    Watson P, Vasen HF, Mecklin JP, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer. 2008;123:444–9.CrossRefGoogle Scholar
  32. 32.
    Barrow E, Robinson L, Alduaij W, et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet. 2009;75:141–9.CrossRefGoogle Scholar
  33. 33.
    Kastrinos F, Stoffel EM, Balmana J, et al. Phenotype comparison of MLH1 and MSH2 mutation carriers in a cohort of 1,914 individuals undergoing clinical genetic testing in the United States. Cancer Epidemiol Biomark Prev. 2008;17:2044–51.CrossRefGoogle Scholar
  34. 34.
    Win AK, Young JP, Lindor NM, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol. 2012;30:958–64.CrossRefGoogle Scholar
  35. 35.
    Canto MI, Harinck F, Hruban RH, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013;62:339–47.CrossRefGoogle Scholar
  36. 36.
    Stoffel E, Mukherjee B, Raymond VM, et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology. 2009;137:1621–7.CrossRefGoogle Scholar
  37. 37.
    Dove-Edwin I, Boks D, Goff S, et al. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer. 2002;94:1708–12.CrossRefGoogle Scholar
  38. 38.
    Gerritzen LH, Hoogerbrugge N, Oei AL, et al. Improvement of endometrial biopsy over transvaginal ultrasound alone for endometrial surveillance in women with Lynch syndrome. Familial Cancer. 2009;8:391–7.CrossRefGoogle Scholar
  39. 39.
    Lecuru F, Le Frere Belda MA, Bats AS, et al. Performance of office hysteroscopy and endometrial biopsy for detecting endometrial disease in women at risk of human non-polyposis colon cancer: a prospective study. Int J Gynecol Cancer. 2008;18:1326–31.CrossRefGoogle Scholar
  40. 40.
    Renkonen-Sinisalo L, Butzow R, Leminen A, et al. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer. 2007;120:821–4.CrossRefGoogle Scholar
  41. 41.
    Rijcken FE, Mourits MJ, Kleibeuker JH, et al. Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol. 2003;91:74–80.CrossRefGoogle Scholar
  42. 42.
    Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. 2006;354:261–9.CrossRefGoogle Scholar
  43. 43.
    Stuckless S, Green J, Dawson L, et al. Impact of gynecological screening in Lynch syndrome carriers with an MSH2 mutation. Clin Genet. 2013;83:359–64.CrossRefGoogle Scholar
  44. 44.
    Auranen A, Joutsiniemi T. A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families. Acta Obstet Gynecol Scand. 2011;90:437–44.CrossRefGoogle Scholar
  45. 45.
    Chen LM, Yang KY, Little SE, et al. Gynecologic cancer prevention in Lynch syndrome/hereditary nonpolyposis colorectal cancer families. Obstet Gynecol. 2007;110:18–25.CrossRefGoogle Scholar
  46. 46.
    Joost P, Therkildsen C, Dominguez-Valentin M, et al. Urinary tract cancer in Lynch syndrome; increased risk in carriers of MSH2 mutations. Urology. 2015;86:1212–7.CrossRefGoogle Scholar
  47. 47.
    Myrhoj T, Andersen MB, Bernstein I. Screening for urinary tract cancer with urine cytology in Lynch syndrome and familial colorectal cancer. Familial Cancer. 2008;7:303–7.CrossRefGoogle Scholar
  48. 48.
    Mork M, Hubosky SG, Roupret M, et al. Lynch syndrome: a primer for urologists and panel recommendations. J Urol. 2015;194:21–9.CrossRefGoogle Scholar
  49. 49.
    Mallinson EK, Newton KF, Bowen J, et al. The impact of screening and genetic registration on mortality and colorectal cancer incidence in familial adenomatous polyposis. Gut. 2010;59:1378–82.CrossRefGoogle Scholar
  50. 50.
    Vasen HF, Moslein G, Alonso A, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut. 2008;57:704–13.CrossRefGoogle Scholar
  51. 51.
    Groen EJ, Roos A, Muntinghe FL, et al. Extra-intestinal manifestations of familial adenomatous polyposis. Ann Surg Oncol. 2008;15:2439–50.CrossRefGoogle Scholar
  52. 52.
    Balmana J, Balaguer F, Cervantes A, et al. Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2013;24(Suppl 6 vi):73–80.Google Scholar
  53. 53.
    Gibbons DC, Sinha A, Phillips RK, et al. Colorectal cancer: no longer the issue in familial adenomatous polyposis? Familial Cancer. 2011;10:11–20.CrossRefGoogle Scholar
  54. 54.
    Jarvinen HJ. Epidemiology of familial adenomatous polyposis in Finland: impact of family screening on the colorectal cancer rate and survival. Gut. 1992;33:357–60.CrossRefGoogle Scholar
  55. 55.
    Friederich P, de Jong AE, Mathus-Vliegen LM, et al. Risk of developing adenomas and carcinomas in the ileal pouch in patients with familial adenomatous polyposis. Clin Gastroenterol Hepatol. 2008;6:1237–42.CrossRefGoogle Scholar
  56. 56.
    Tajika M, Nakamura T, Nakahara O, et al. Prevalence of adenomas and carcinomas in the ileal pouch after proctocolectomy in patients with familial adenomatous polyposis. J Gastrointest Surg. 2009;13:1266–73.CrossRefGoogle Scholar
  57. 57.
    Smith JC, Schaffer MW, Ballard BR, et al. Adenocarcinomas after prophylactic surgery for familial adenomatous polyposis. J Cancer Ther. 2013;4:260–70.CrossRefGoogle Scholar
  58. 58.
    Matsumoto T, Esaki M, Fujisawa R, et al. Chromoendoscopy, narrow-band imaging colonoscopy, and autofluorescence colonoscopy for detection of diminutive colorectal neoplasia in familial adenomatous polyposis. Dis Colon Rectum. 2009;52:1160–5.CrossRefGoogle Scholar
  59. 59.
    Biasco G, Pantaleo MA, Di Febo G, et al. Risk of duodenal cancer in patients with familial adenomatous polyposis. Gut. 2004;53:1547; author reply 1547PubMedPubMedCentralGoogle Scholar
  60. 60.
    Spigelman AD, Williams CB, Talbot IC, et al. Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Lancet. 1989;2:783–5.CrossRefGoogle Scholar
  61. 61.
    Bulow S, Bjork J, Christensen IJ, et al. Duodenal adenomatosis in familial adenomatous polyposis. Gut. 2004;53:381–6.CrossRefGoogle Scholar
  62. 62.
    Brosens LA, Keller JJ, Offerhaus GJ, et al. Prevention and management of duodenal polyps in familial adenomatous polyposis. Gut. 2005;54:1034–43.CrossRefGoogle Scholar
  63. 63.
    Yamada A, Watabe H, Iwama T, et al. The prevalence of small intestinal polyps in patients with familial adenomatous polyposis: a prospective capsule endoscopy study. Familial Cancer. 2014;13:23–8.CrossRefGoogle Scholar
  64. 64.
    Sarre RG, Frost AG, Jagelman DG, et al. Gastric and duodenal polyps in familial adenomatous polyposis: a prospective study of the nature and prevalence of upper gastrointestinal polyps. Gut. 1987;28:306–14.CrossRefGoogle Scholar
  65. 65.
    Bianchi LK, Burke CA, Bennett AE, et al. Fundic gland polyp dysplasia is common in familial adenomatous polyposis. Clin Gastroenterol Hepatol. 2008;6:180–5.CrossRefGoogle Scholar
  66. 66.
    Aretz S, Stienen D, Friedrichs N, et al. Somatic APC mosaicism: a frequent cause of familial adenomatous polyposis (FAP). Hum Mutat. 2007;28:985–92.CrossRefGoogle Scholar
  67. 67.
    Balaguer F, Castellvi-Bel S, Castells A, et al. Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study. Clin Gastroenterol Hepatol. 2007;5:379–87.CrossRefGoogle Scholar
  68. 68.
    Grover S, Kastrinos F, Steyerberg EW, et al. Prevalence and phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomas. JAMA. 2012;308:485–92.CrossRefGoogle Scholar
  69. 69.
    Vogt S, Jones N, Christian D, et al. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology. 2009;137:1976–85 e1–10.CrossRefGoogle Scholar
  70. 70.
    Nielsen M, Morreau H, Vasen HF, et al. MUTYH-associated polyposis (MAP). Crit Rev Oncol Hematol. 2011;79:1–16.CrossRefGoogle Scholar
  71. 71.
    Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18:325–32.CrossRefGoogle Scholar
  72. 72.
    Howe JR, Sayed MG, Ahmed AF, et al. The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations. J Med Genet. 2004;41:484–91.CrossRefGoogle Scholar
  73. 73.
    Latchford AR, Neale K, Phillips RK, et al. Juvenile polyposis syndrome: a study of genotype, phenotype, and long-term outcome. Dis Colon Rectum. 2012;55:1038–43.CrossRefGoogle Scholar
  74. 74.
    Schreibman IR, Baker M, Amos C, et al. The hamartomatous polyposis syndromes: a clinical and molecular review. Am J Gastroenterol. 2005;100:476–90.CrossRefGoogle Scholar
  75. 75.
    Dunlop MG, British Society for G, Association of Coloproctology for Great B, et al. Guidance on gastrointestinal surveillance for hereditary non-polyposis colorectal cancer, familial adenomatous polypolis, juvenile polyposis, and Peutz-Jeghers syndrome. Gut. 2002;51(Suppl 5):V21–7.CrossRefGoogle Scholar
  76. 76.
    Beggs AD, Latchford AR, Vasen HF, et al. Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut. 2010;59:975–86.CrossRefGoogle Scholar
  77. 77.
    Tomlinson IP, Houlston RS. Peutz-Jeghers syndrome. J Med Genet. 1997;34:1007–11.CrossRefGoogle Scholar
  78. 78.
    van Lier MG, Westerman AM, Wagner A, et al. High cancer risk and increased mortality in patients with Peutz-Jeghers syndrome. Gut. 2011;60:141–7.CrossRefGoogle Scholar
  79. 79.
    Kastrinos F, Syngal S. Screening patients with colorectal cancer for Lynch syndrome: what are we waiting for? J Clin Oncol. 2012;30:1024–7.CrossRefGoogle Scholar
  80. 80.
    Carballal S, Rodriguez-Alcalde D, Moreira L, et al. Colorectal cancer risk factors in patients with serrated polyposis syndrome: a large multicentre study. Gut. 2015;65(11):1829–37.CrossRefGoogle Scholar
  81. 81.
    Boparai KS, van den Broek FJ, van Eeden S, et al. Increased polyp detection using narrow band imaging compared with high resolution endoscopy in patients with hyperplastic polyposis syndrome. Endoscopy. 2011;43:676–82.CrossRefGoogle Scholar
  82. 82.
    Pellise M, Diaz Tasende J, Balaguer F, et al. Technical review of advanced diagnostic endoscopy in patients at high risk of colorectal cancer. Gastroenterol Hepatol. 2012;35:278–92.CrossRefGoogle Scholar
  83. 83.
    Vasen HF, Ghorbanoghli Z, Bourdeaut F, et al. Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium “Care for CMMR-D” (C4CMMR-D). J Med Genet. 2014;51:283–93.CrossRefGoogle Scholar
  84. 84.
    Durno C, Boland CR, Cohen S, et al. Recommendations on surveillance and management of Biallelic Mismatch Repair Deficiency (BMMRD) syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2017;30175-0(17):S0016–5085.Google Scholar
  85. 85.
    Engel C, Loeffler M, Steinke V, et al. Risks of less common cancers in proven mutation carriers with Lynch syndrome. J Clin Oncol. 2012;30:4409–15.CrossRefGoogle Scholar
  86. 86.
    Kastrinos F, Stoffel EM. History, genetics, and strategies for cancer prevention in Lynch syndrome. Clin Gastroenterol Hepatol. 2014;12:715–27.CrossRefGoogle Scholar
  87. 87.
    Stoffel EM, Mangu PB, Gruber SB, et al. Hereditary colorectal cancer syndromes: American Society of Clinical Oncology clinical practice guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology clinical practice guidelines. J Clin Oncol. 2015;33:209–17.CrossRefGoogle Scholar
  88. 88.
    Guillen-Ponce C, Serrano R, Sanchez-Heras AB, et al. Clinical guideline seom: hereditary colorectal cancer. Clin Transl Oncol. 2015;17:962–71.CrossRefGoogle Scholar
  89. 89.
    Boparai KS, Reitsma JB, Lemmens V, et al. Increased colorectal cancer risk in first-degree relatives of patients with hyperplastic polyposis syndrome. Gut. 2010;59:1222–5.CrossRefGoogle Scholar
  90. 90.
    National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Colorectal (Version 2.2016). Accessed April 6, 2017.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Medical OncologyHospital Universitari Vall d’Hebron, VHIOBarcelonaSpain
  2. 2.Department of GastroenterologyHospital Clínic, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), Institut de Investigació August Pi i Sunyer (IDIBAPS)BarcelonaSpain
  3. 3.Hereditary Cancer Program, Catalan Institute of Oncology, Centro de Investigación Biomédica en Red de Cáncer (CIBEROnc), Institut d’Investigació Biomèdica de Girona (IdIBGi)GironaSpain

Personalised recommendations